



28 June 2024

cyclomedica
technegas
ultralute

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

NOTICE UNDER SECTION 708A(5) OF THE CORPORATIONS ACT 2001 (CTH)

On 28 June 2024, Cyclopharm Limited (the “**Company**”) announced the issue of 43,900 new fully paid ordinary shares at \$1.48 per share as part of a performance bonus.

Accordingly, the Company advises:

- 1 The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth) (the “**Act**”).
- 2 This notice is being given under section 708A(5)(e) of the Act.
- 3 As at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (b) sections 674 and 674A of the Act.
- 4 As at the date of this notice, there is no excluded information as defined in sections 708A(7) and 708A(8) of the Act which is required to be disclosed by the Company.

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411